Phathom Pharmaceuticals, Inc. (PHAT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.26 |
| Open | 8.24 |
| Bid | 7.99 x 800 |
| Ask | 9.36 x 800 |
| Day's Range | 8.24 - 8.78 |
| 52 Week Range | 5.84 - 17.02 |
| Volume | |
| Avg. Volume | 529,281 |
| Market Cap | 482.639M |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.81 |
| Earnings Date | Feb 26, 2024 - Mar 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.29 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PHAT
Related Research
- Phathom Pharmaceuticals, Inc.Daily – Vickers Top Buyers & Sellers for 04/12/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat8 months agoArgus Research
GlobeNewswirePhathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERDJuly 19, 2024 PDUFA target action date assigned by the FDA FLORHAM PARK, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the FDA has
- GlobeNewswire
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channelVOQUEZNA tablets in 30-count bottles are now commercially available for the healing and maintenance of healing of all severities of Erosive GERD, and relief of heartburn associated with Erosive GERD1 FLORHAM PARK, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmac
GuruFocus.comPhathom Pharmaceuticals Inc (PHAT) Reports Q3 2023 Financial Results
Key Takeaways from the Third Quarter Earnings Report
